Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$10.70 - $115.60
Next Earnings Date
Apr 30 2025
Next Earnings Date
Apr 30 2025
Latest price
Market Cap | $2.97B |
EV | $2.94B |
Shares Outstanding | 28.26M |
Beta | 2.00 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $107.83 |
P/E 2025E | 114.88x |
P/Revenue 2025E | 8.27x |
Revenue | 12.90% |
EPS | - |
Operating Cash Flow | 46.90% |
Free Cash Flow | - |
Revenue | 16.50% |
EPS | 126.70% |
Operating Cash Flow | - |
Free Cash Flow | 196.10% |
Gross Margin 2025E | 66.25% |
Net Profit Margin 2025E | -4.49% |
ROE 2025E | - |
ROCE 2024 | -22.10% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
GeneDx Holdings Corp.
WGS
Sector
Healthcare
Industry
Medical - Healthcare Information Services
CEO
Stueland, Katherine
Employees
1,000
Website
www.genedx.comIPO Date
2020-11-04
Headquarters
North Tower, 6th Floor, 333 Ludlow Street, Stamford, Connecticut, 06902, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved